Donnerstag, 2. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

Rekrutierend

NCT-Nummer:
NCT04602533

Studienbeginn:
Dezember 2020

Letztes Update:
05.06.2023

Wirkstoff:
Durvalumab, Standard of Care

Indikation (Clinical Trials):
Lung Neoplasms, Small Cell Lung Carcinoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Michael Hopp

Collaborator:
AstraZeneca

Studienleiter

Thomas Wehler, Professor
Principal Investigator
Universitätsklinikum Gießen Marburg

Kontakt

Thomas Wehler, Professor Dr med
Kontakt:
Phone: +49 641985
Phone (ext.): 58544
E-Mail: Thomas.wehler@innere.med.uni-giessen.de» Kontaktdaten anzeigen

Studienlocations
(3 von 12)

Klinikum Kassel GmbH-Klinik für Onkologie und Hämatologie
34125 Kassel
(Hessen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Martin Wolf, Prof Dr med
E-Mail: martin.wolf.studie@gnh.net» Ansprechpartner anzeigen
Johannes Wesling Klinikum Minden
32429 Minden
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Parvis Sadjadian, Dr med
E-Mail: parvis.sadjadian@muehlenkreiskliniken.de» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Detailed Description:

The trial is subdivided in a safety run-in phase and a randomized part with the induction

phase (Radiochemotherapy ± Durvalumab and including prophylactic cranial irradiation (PCI; if

clinically indicated and according to local standard)) followed by the maintenance phase. The

trial starts with the safety run-in phase of 6 patients in Durvalumab group. After the

completion of the first cycle of all 6 patients a safety interim analysis will be performed.

Study should be discontinued if ≥ 2 out of 6 patients within safety run-in phase (first

cycle):

- show more than 2 AEs CTCAE grade ≥3 related to study drug Durvalumab

- or develop pneumonitis (CTCAE grade ≥2)

- or drop out, Otherwise, the trial can continue with randomization. Eligible patients

will be randomized to Durvalumab group or standard of care group 2:1.

The safety interim analysis was performed in Q4 2021. The independent DMC has recommended the

continuation of the trial.

Induction phase:

Durvalumab group: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and

Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant

Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours

or more between fractions) with start at latest at beginning of cycle 3, ideally during cycle

1) and additional Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles according to

randomization followed by prophylactic cranial irradiation (PCI, if clinically indicated and

according to local standard at any time after completion of radio-chemotherapy))

Control group: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and

Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant

Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours

or more between fractions with start at latest at beginning of cycle 3, ideally during cycle

1) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according

to local standard at any time after completion of radio-chemotherapy)

# Due to the potential toxicity of Cisplatin 75 mg/m² D1, a Cisplatin split dose with 40

mg/m² on D1 and D8 is alternatively allowed. A switch from Cisplatin to Carboplatin AUC 5 D1

(due to new contraindication to Cisplatin) or split dose Carboplatin (AUC 2.5 D1 and D8) is

also allowed. In case of initial contraindication to Cisplatin (i.e. renal dysfuction) at

baseline, treatment can be started with Carboplatin once every 3 weeks (q21) AUC 5 D1, or

split dose AUC 2.5 D1 and D8. A simultaneous administration of platinum-based chemotherapy

(preferred Cisplatin) and radiotherapy for at least 2 cycles should be performed.

Maintenance phase:

In Durvalumab group patients will be treated with Durvalumab once every 4 weeks until disease

progression (radiologic or clinical progression) or unacceptable toxicities, if patients show

at least stable disease after induction phase. Patients with PD after induction phase will

have EoT visit and will be followed up until death.

Patients in control group will have EoT visit and will receive standard of care treatment

until PD and thereafter will be followed up until death.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Signed and dated informed consent of the subject must be available before start of any

specific trial procedures

- Male or female ≥ 18 years

- Histological confirmed limited disease small cell lung cancer (stage 2 and 3; T1a-4,

N1-3, M0 according UICC8 criteria; if primarius is not eligible as RECIST1.1 target

lesion (in cases with T1a and T1b) at least one lymph node must meet RECIST1.1

criteria for target lesion (≥15 mm short axis))

- Availability of tumor tissue or fresh tumor material for translational research by

central lab testing

- ECOG PS 0 - 1

- At least one measurable lesion according RECIST 1.1

- Body weight > 30 kg

- Adequate normal organ function

1. Hemoglobin ≥ 9.0 g/dL

2. Absolute neutrophil count (ANC) ≥ 1.5 x109/L

3. Platelet count ≥ 100 x109/L

4. AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal

5. Serum Bilirubin ≤ 1.5 x institutional upper limit of normal

6. Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min for Carboplatin, ≥ 60

mL/min fpr Cisplatin, calculated by the Cockcroft-Gault formula

- Life expectancy of at least 12 weeks in the discretion of the investigator

- Ability of subject to understand nature, importance and individual consequences of

clinical trial

Exclusion Criteria:

- Extensive disease small cell lung cancer (Tx, Nx, M1; stage IV)

- Major surgical process within 28 day prior first dose of IMP and/or Radiochemotherapy

- History of allogenic organ transplantation

- Active or prior documented autoimmune or inflammatory disorder (including inflammatory

bowel disease [e.g. colitis or Crohn's disease], diverticulitis [with the exception of

diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome or Wegener

syndrome [granulomatosis with polyangiitis], Graves' disease, rheumatoid arthritis,

hypophysitis, uveitis, etc.). The following are exceptions to this criterion:

1. Patients with vitiligo or alopecia

2. Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on

hormone replacement

3. Patients with any chronic skin condition that not required systemic therapy

4. Patients without active disease in the last 5 years may be included but only

after consultation with the study physician

5. Patients with celiac disease controlled by diet alone

- Uncontrolled intercurrent illness (i.e. active infection, symptomatic congestive heart

failure, uncontrolled hypertension, unstable angina pectoris, interstitial lung

disease, serious chronic gastrointestinal conditions (i.e. diarrhea), psychiatric

illness)

- History of another primary malignancy in the last 5 years, except adequately treated

nonmelanoma skin cancer, adequately treated carcinoma in situ (without evidence of

disease)

- History of leptomeningeal carcinomatosis, or brain metastases

- Known HIV positive and/or active infection including tuberculosis (clinical evaluation

that includes clinical history, physical examination and radiographic findings, and TB

testing in line with local practice), hepatitis B (known positive HBV surface antigen

(HBsAg) result), hepatitis C. Patients with a past or resolved HBV infection (defined

as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are

eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if

polymerase chain reaction is negative for HCV RNA.

- Current or prior use of immunosuppressive medication within 14 days before the first

dose.The following are exceptions to this criterion:

1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra

articular injection)

2. Systemic corticosteroids at physiologic doses not exceeding 10 mg/day of

prednisone or its equivalent

3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan

premedication)

- Receipt of live attenuated vaccine within 30 days prior to the first dose of IMP

- Participation in another clinical trial with an investigational product within the

last 30 days (unless during follow-up period of an interventional study)

- Known hypersensitivity to one of the ingredients

- Medical or psychological conditions that would jeopardize an adequate and orderly

completion of the trial

- Pregnancy, lactation and contraception

1. Women who are pregnant, nursing or who plan to become pregnant while in the trial

2. Women of child-bearing potential (WOCBP) and men who are able to father a child,

unwilling to be abstinent or use highly effective methods of birth control that

result in a low failure rate of less than 1% per year when used consistently and

correctly beginning at informed consent, for the duration of drug treatment and

for the drug out washout period (90 days after last dose of Durvalumab and/or 6

months after last dose of cisplatin/carboplatin and etoposide).

- Patients who are legally institutionalized

Studien-Rationale

Primary outcome:

1. Progression-free survival (PFS) (Time Frame - 18 months):
Progression-free survival (PFS) after 18 months according to iRECIST



Secondary outcome:

1. Progression-free survival (PSF) after other assessments (Time Frame - 12 months):
Time between first application of trial medication to date of disease progression or death due to any cause

2. Overall survival (OS) (Time Frame - 18 months):
Time between first application of trial medication to date of death due to any cause

3. Overall response rate (ORR) (Time Frame - 18 months):
Complete Response or Partial Response according to iRECIST

4. Disease control rate (DCR) (Time Frame - 18 months):
Complete Response, Partial Response or Stable Disease according to iRECIST

5. Quality of Life Questionnaire - Cancer 30 (QLQ-C30) (Time Frame - 18 months):
Symptom control assessed by patient-reported quality of life (QoL) with QLQ-C30. The score ranges from 0 to 100. The higher the score the better the outcome.

6. Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13) (Time Frame - 18 months):
Symptom control assessed by patient-reported quality of life (QoL) with QLQ-LC13. The scores ranges from 0 to 100. The higher the score the better the outcome.

7. EuroQol five dimension scale (EQ-5D) (Time Frame - 18 months):
Symptom control assessed by patient-reported quality of life (QoL) with EQ-5D. The score consists of 5 items on a three step scale and a VAS scale ranging from 0 to 100. The lower the score on the three step scales the better the outcome and the higher the score on the VAS scale the better the outcome.

8. Adverse Events (Time Frame - 18 months):
Treatment emergent adverse events during treatment

Studien-Arme

  • Experimental: Durvalumab
    Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.
  • Other: standard of care
    Induction phase: Radiochemotherapy according to guideline Maintenance: Standard of care

Geprüfte Regime

  • Durvalumab (IMFINZI®):
    Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.
  • standard of care:
    Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) with start at latest at beginning of cycle 3, ideally during cycle 1) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according to local standard at any time after completion of radio-chemotherapy)) A simultaneous administration of platinum-based chemotherapy (preferred Cisplatin) and radiotherapy for at least 2 cycles should be performed.

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.